None listed
Conditions
Brief summary
Angina is a medical term used to describe pain (usually felt in the chest) due to coronary artery disease causing reduced blood flow to the heart. We are investigating the use of G-CSF to treat chronic angina in patients who have failed standard treatment with medications and or coronary stenting/coronary artery bypass surgery. G-CSF is a man made version of a naturally occuring hormone. There is experimental evidence that G-CSF can stimulate the formation of new blood vessels in the heart and protect heart muscle cells. Through these effects, we hypothesise that patients will derive improvements in blood flow to the heart and hence angina symptoms. We will be measuring the effects of G-CSF on blood flow to the heart with cardiac magnetic resonance imaging (MRI scan).
Interventions
Granulocyte colony stimulating factor
Subcutaneous
Commenced at 4.5 mcg/kg/d
Three 5 day cycles (each cycle fortnight apart)
Sponsors
St Vincent's Hospital
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Canadian class III/IV angina2. Angiographically proven coronary artery disease3. Demonstrable reversible ischaemia on adenosine stress cardiac MRI.
Exclusion criteria
1. MI < 3 months2. Unstable angina3. Uncontrolled heart failure. 4. EF < 20%5. Significant (>50%) left main or left main equivalent disease6. Advanced coronary artery bypass graft disease.7. Factors preventing MRI including permanent pacemaker, implantable defibrillator, neurostimulator, severe claustrophobia8. Contraindications to adenosine including high degree heart block, severe bronchospasm.9. Proliferative retinopathy
Outcome results
None listed